Sector ratings Genmab A/S

Equities

Delayed Nasdaq Copenhagen Other stock markets 11:20:00 2026-05-13 EDT			5-day change	1st Jan Change
1,684.00 ^DKK	-1.66%		-4.24%	-16.92%

05-12	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
05-11	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
GENMAB A/S	16.15B		A
ARGENX SE	50.39B		A
WUXI APPTEC CO., LTD.	46.03B		AAA
INSMED INCORPORATED	25.06B	-	A	-		-
BIONTECH SE	23.26B	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	17.24B		AAA
AKESO, INC.	14.56B		B
SUMMIT THERAPEUTICS INC.	14.08B	-	-	-		-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	12.94B	-	AA	-		-
EXELIXIS, INC.	12.84B		BB
MADRIGAL PHARMACEUTICALS, INC.	12.45B	-	B	-		-
ARROWHEAD PHARMACEUTICALS, INC.	11.22B	-	BB	-		-
CYTOKINETICS, INCORPORATED	9.79B	-	AA	-		-
PHARMAESSENTIA CORPORATION	9.2B		AA
REMEGEN CO., LTD.	8.42B		-
IMMUNITYBIO, INC.	8.54B	-	CCC	-		-
SAMSUNG EPIS HOLDINGS CO., LTD.	8.79B		AA				-
NUVALENT, INC.	8.25B	-	CCC	-		-
CEREVEL THERAPEUTICS HOLDINGS, INC.	8.19B	-	-	-	-	-	-	-
VAXCYTE, INC.	7.73B	-	BBB	-		-
Average	16.26B		A
Weighted average by Cap.			A